Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Doxorubicin |
| Synonyms | |
| Therapy Description |
Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02094872 | Phase II | Doxorubicin | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | Completed | USA | 0 |
| NCT02881086 | Phase III | Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Completed | DEU | 0 |
| NCT06088290 | Phase II | Doxorubicin Doxorubicin + Lurbinectedin | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
| NCT03145558 | Phase II | Doxorubicin Tirapazamine | TATE Versus TACE in Intermediate Stage HCC (TATE) | Terminated | USA | 0 |
| NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
| NCT03020030 | Phase III | Nelarabine Dexrazoxane Asparaginase Vincristine Sulfate Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | Active, not recruiting | USA | CAN | 0 |
| NCT03571321 | Phase I | Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Sulfate Rituximab Doxorubicin | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
| NCT01750073 | Phase II | Doxorubicin Trastuzumab Cyclophosphamide + Paclitaxel | Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03150693 | Phase III | Rituximab Doxorubicin Mercaptopurine Methotrexate Cyclophosphamide + Cytarabine Thioguanine Allopurinol Daunorubicin Dexamethasone Vincristine Sulfate Inotuzumab ozogamicin | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Suspended | USA | CAN | 0 |
| NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
| NCT03007147 | Phase III | Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Sulfate Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | SWE | NZL | NLD | ITA | ISR | FRA | FIN | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
| NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Completed | USA | POL | ITA | GBR | ESP | DEU | CAN | BRA | BEL | AUS | 3 |
| NCT02677116 | Phase I | Doxorubicin Ifosfamide Irinotecan + Vincristine Sulfate Olaratumab | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | Completed | USA | 1 |
| NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Recruiting | ESP | 0 |
| NCT03004287 | Phase II | Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Active, not recruiting | USA | 0 |
| NCT01655693 | Phase III | Doxorubicin | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) | Completed | USA | TUR | LBN | ITA | HUN | FRA | ESP | DEU | BEL | AUT | 1 |
| NCT06528496 | Phase II | Irinotecan Doxorubicin Ifosfamide Sargramostim Etoposide Temozolomide Carboplatin Naxitamab Vincristine Sulfate Topotecan Cyclophosphamide | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Recruiting | USA | 0 |
| NCT05218499 | Phase II | BI 907828 Doxorubicin | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | Active, not recruiting | USA | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 5 |
| NCT01358877 | Phase III | Pertuzumab Epirubicin Cyclophosphamide Paclitaxel Docetaxel Trastuzumab Fluorouracil Carboplatin Doxorubicin | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) | Completed | USA | SWE | SVN | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | ARG | 17 |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT02502266 | Phase II | Topotecan Paclitaxel Doxorubicin Olaparib Cediranib | Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 3 |
| NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
| NCT01375699 | Phase I | Doxorubicin | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | Completed | USA | 0 |
| NCT01857934 | Phase II | Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan | Therapy for Children With Advanced Stage Neuroblastoma | Active, not recruiting | USA | 0 |
| NCT03860844 | Phase II | Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | Terminated | USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG | 4 |
| NCT02192021 | Phase I | Doxorubicin | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | Completed | USA | 0 |
| NCT03319901 | Phase I | Cytarabine Mercaptopurine Methotrexate Cyclophosphamide Venetoclax Doxorubicin Etoposide Vincristine Sulfate | Venetoclax and Chemotherapy In ALL | Recruiting | USA | 0 |
| NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Completed | USA | CAN | 0 |
| NCT06422806 | Phase III | Doxorubicin Doxorubicin + Pembrolizumab | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Recruiting | USA | 0 |
| NCT02312245 | Phase II | Topotecan Doxorubicin Paclitaxel Gemcitabine | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
| NCT06377566 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Gemcitabine Dacarbazine Doxorubicin Pembrolizumab Brentuximab vedotin Vinorelbine Vinblastine | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Recruiting | USA | 0 |
| NCT02494713 | Phase II | Degarelix Estramustine Docetaxel Doxorubicin Ketoconazole | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | Terminated | USA | 0 |
| NCT03113500 | Phase II | Etoposide Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone Doxorubicin Cyclophosphamide Prednisone | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | Active, not recruiting | USA | CAN | 0 |
| NCT00549848 | Phase III | Daunorubicin + Pegaspargase + Vincristine Sulfate Cytarabine Mercaptopurine Thioguanine Clofarabine + Cyclophosphamide + Etoposide Methotrexate Dasatinib Doxorubicin Dexamethasone | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Completed | USA | 0 |
| NCT03117751 | Phase II | Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Active, not recruiting | USA | AUS | 0 |
| NCT06132958 | Phase III | Paclitaxel Doxorubicin SKB264 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT01523977 | Phase I | Prednisone Everolimus Vincristine Sulfate Doxorubicin Pegaspargase | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | Completed | USA | 0 |
| NCT04204941 | Phase III | Doxorubicin Doxorubicin + Tazemetostat | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | Recruiting | USA | GBR | CAN | 1 |
| NCT02419755 | Phase II | Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | Terminated | USA | 0 |
| NCT03023046 | Phase II | Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Sulfate | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Completed | USA | 0 |
| NCT06486441 | Phase III | Doxorubicin Paclitaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) (ASCENT-GYN-01) | Recruiting | USA | POL | 5 |
| NCT01319981 | Phase II | Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Sulfate Cyclophosphamide | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | Completed | USA | 0 |
| NCT02580058 | Phase III | Doxorubicin Avelumab | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | Completed | USA | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 6 |
| NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Unknown status | USA | 0 |
| NCT00980460 | Phase III | Irinotecan + Temsirolimus + Vincristine Sulfate Cisplatin + Fluorouracil + Vincristine Sulfate Doxorubicin | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | Active, not recruiting | USA | CAN | BRA | AUS | 2 |
| NCT02460991 | Phase I | Sorafenib Doxorubicin | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
| NCT04874311 | Phase II | Bintrafusp alfa + Doxorubicin Doxorubicin | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) | Recruiting | FRA | 0 |
| NCT02419495 | Phase I | Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin | Selinexor in Combination With Standard Chemotherapy | Terminated | USA | 0 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT01815294 | Phase I | Doxorubicin Pegylated liposomal doxorubicin | A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer | Completed | USA | GBR | ESP | BEL | 0 |
| NCT06245889 | Phase II | Cyclophosphamide Olaparib Carboplatin + Paclitaxel + Pembrolizumab Doxorubicin Capecitabine | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT) | Recruiting | USA | 0 |
| NCT02451943 | Phase III | Olaratumab Doxorubicin | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
| NCT03420014 | Phase II | Doxorubicin + Onfekafusp alfa Doxorubicin | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (FIBROSARC US) | Recruiting | USA | 0 |
| NCT02112916 | Phase III | Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
| NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Completed | USA | ESP | CAN | BEL | 0 |
| NCT01015833 | Phase III | Doxorubicin Sorafenib | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Completed | USA | CAN | 1 |
| NCT03126916 | Phase III | Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Active, not recruiting | USA | CAN | 1 |
| NCT03517449 | Phase III | Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 6 |
| NCT00074490 | Phase II | Cyclophosphamide Cyclosporine Rituximab Doxorubicin Etoposide Filgrastim Vincristine Sulfate Fludarabine | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | Terminated | USA | 0 |
| NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | POL | NLD | ITA | ISR | HUN | FRA | ESP | DNK | CAN | AUS | 2 |
| NCT04650984 | Phase III | Doxorubicin + Onfekafusp alfa Doxorubicin | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC) | Recruiting | POL | ITA | FRA | ESP | DEU | 0 |
| NCT01459380 | Phase I | Carboplatin Doxorubicin Veliparib Bevacizumab | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | 0 |
CKB BOOST